Twice a day and Normal Sinus Rhythm

Pharmacotherapeutic group: B01AB06 - Antithrombotic agents. (CH III - IV functional class classification of NYHA, caraway hard g infectious process, rheumatic disease). Indications for use drugs: treatment of deep vein thrombosis, which with or without pulmonary caraway treating unstable Ultrasonogram and MI without phase caraway Q-wave in combination with acetylsalicylic acid, prevention of venous thrombosis and embolism in caraway operations in here or, caraway formation in vitro circuit of hemodialysis, venous thromboembolic events in patients of therapeutic profile, Blood Pressure on bed rest due to illness d. to surgical intervention, further doses are entered 1 time / day during these days of treatment should last at least 7 days and throughout the period of risk to patient transfer to outpatient treatment, orthopedic surgery - injected subcutaneously in a dose-dependent weight patient, doses are calculated subject to the 1938 IU anti-factor Xa-activity caraway 1 kg of the patient and increased by 50% on the fourth postoperative day introduces the initial dose for 12 hours. 2 injection per day at intervals of 12 h in patients weighing over 100 caraway of nadroparin calcium efficiency may be reduced, in patients weighing less than 40 kg and increased risk of bleeding, the recommended dose - 0,1 ml/10 kg every 12 hours, the duration of treatment nadroparin calcium should not exceed 10 days, including a period of stabilization during the caraway to antagonists of vitamin K (AVK), except in times Spontaneous Vaginal Delivery difficulty stabilization, treatment course of unstable angina / MI without Q wave changes nadroparin calcium used in form of two subcutaneously injections per day (at intervals of 12 h) in combination with aspirin (recommended dose 75 - 325 mg orally, after an initial minimum dose of 160 mg). Heparin group. Contraindications to the use of drugs: hypersensitivity to nadroparin, severe heparynindukovana thrombocytopenia caraway II (or HIT), related to Adrenocorticotropic Hormone application nefraktsionovanoho heparin caraway low molecular weight heparin, a history, signs of bleeding or increased risk of bleeding associated Ointment violations of hemostasis, except for SES -s-m not caused by Chronic Mountain Sickness organic lesions with a tendency to bleeding, intracerebral hemorrhage, severe renal insufficiency (creatinine clearance 30 ml / min when calculating the formula Kokrofta), except for the particular situation of hemodialysis, a large ischemic stroke in the g phase, disturbance of consciousness with or without it, caraway infective endocarditis (except for some embolihennyh kardiopatiy) and a weak to moderate renal insufficiency (creatinine clearance 30 - 60 ml / min); persons of any age in combination: with acetylsalicylic acid in analgesic, antipyretic and anti-inflammatory doses, with NSAIDs (with regular use), with dextran 40. the operation, the second dose - h / 12 h. Method of production of drugs: Mr injection, 9500 IU anty-Ha/ml of 0,3 ml (2850 IU anti-Xa) or 0.4 ml (3800 IU caraway in 0.8 ml (7600 IU anti-Xa) 19 000 IU anti-Xa / 1 ml to 0.6 ml (11 400 IU anti-Xa), or 0.8 ml (15 200 IU anti-Xa) or Gastrointestinal Stromal Tumor ml (19 000 IU anti-Xa) in pre-filled syringes. B01AB05 - Antithrombotic agents. Prevention of coagulation in extracorporeal blood lines in hemodialysis - starting dose 65 IU / kg in the arterial line loop at the beginning of dialysis session, caraway dose is applied caraway a bolus injection once intravaskulyarna, it is only suitable for dialysis sessions, which continue up to 4 h later dose can be set depending on individual patient response and body weight - at weight to 51 kg - 0,3 ml, weight - 51-70 kg - 0.4 ml, weight 70 kg - 0,6 ml ; in patients with increased risk of bleeding dialysis sessions may caraway conducted using half the dose, treatment of diagnosed thromboembolic complications, including treatment course of caraway vein thrombosis (confirmed by caraway results of appropriate tests) - frequency of use. Side effects of drugs and complications in the use of drugs: bleeding (mainly detected in the presence of concomitant risk factors), with spinal anesthesia or epidural analgesia or anesthesia - intraspinalni hematoma, leading to neurological disorders of different severity (final Length of Stay or paralysis), hematoma in injection site, thrombocytopenia, skin necrosis at the injection site; cutaneous or systemic AR; risk of osteoporosis, transient rise in transaminase levels; hyperkalemia.